Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers

Psychiatry Research

Volumn 64, Issue 3, 1996, Pages 147-159

  Maes, Michael ^a,b,c   Meltzer, Herbert Y ^b,c  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Body temperature; Cortisol; Prolactin; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PLACEBO; PROLACTIN;

ADULT; ARTICLE; BEHAVIOR; BODY TEMPERATURE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AFFECT; BODY TEMPERATURE; HUMANS; HYDROCORTISONE; MALE; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN AGONISTS; SINGLE-BLIND METHOD;

EID: 0030590644     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(96)02917-4     Document Type: Article

References (59)

1. Aloi, J.A., Insel, T.R., Mueller, E.A. and Murphy, D.L. (1984) Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci 34, 1325-1331.
2. American Psychiatric Association. (1987) DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd rev. edn. American Psychiatric Press, Washington, DC.
3. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85, 19-29.
4. Asnis, G.M., Wetzler, S., Sanderson, W.C., Kahn, R.S. and van Praag, H.M. (1992) Functional interrelationship of serotonin and norepinephrine: Cortisol responses to mCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 43, 65-76.
5. Bagdy, G., Szemerdi, K., Kanyicska, B. and Murphy, D.L. (1989) Different serotonin receptors mediate blood-pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. J Pharmacol Exp Ther 250, 72-78.
6. Bennett, J.P., Enna, S.J., Bylund, D.B., Gillin, J.C., Wyatt, R.J. and Snyder, S.H. (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36, 927-934.
7. Bleich, A., Brown, S.L., Kahn, R. and van Praag, H.M. (1988) The role of serotonin in schizophrenia. Schizophr Bull 14; 297-315.
8. Breier, A., Kirkpatrick, B. and Buchanan, R.W. (1993) Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 34, 492-494.
9. Ceulemans, D., Gelders, Y., Hoppenbrouwers, M.-L., Reyntjes, A. and Janssen, P. (1985) Effects of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 85, 329-332.
10. Clineschmidt, B.V. (1979) Minireview. MK-212: A serotonin-like agonist in the CNS. Gen Pharmacol 10, 287-290.
11. Clineschmidt, B.V. and McGuffin, J.C. (1978) Pharmacological differentiation of the central 5-hydroxytryptamine-like actions of MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine), p-methoxyamphetamine and fenfluramine in an in vivo model system. Eur J Pharmacol 50, 369-375.
12. 1C receptors. J Pharmacol Exp Ther 242, 552-557.
13. Cowen, P.J., Gadhvi, H., Gosden, B. and Kolakowska, T. (1985) Responses of prolactin and growth hormone to L-tryptophan infusion: Effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology 86, 164-169.
14. 1c receptors. Trends Pharmacol Sci 11, 181-182.
15. Duinkerke, S.J., Botter, P.A., Jansen, A.A.I., Van Dongen, P.A.M., Van Haaften, A.J., Boom, A.J., Van Laarhoven, J.H.M. and Busard, H.L.S. (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: A placebo-controlled double-blind trial. Br J Psychiatry 163, 451-455.
16. Endicott, J. and Spitzer, R.L. (1978) A diagnostic interview; The Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35, 837-844.
17. Fuller, R.W. (1981) Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32, 118-127.
18. 2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9, 325-327.
19. 2 agonists or antagonists? Neuropsychopharmacology 3, 509-517.
20. 3 serotonin receptors: Results of a structure-affinity study. Eur J Pharmacol 168, 387-392.
21. 1A receptors. Neuropharmacology 25, 1307-1313.
22. Hamik, P. and Peroutka, S. (1989) 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25, 569-575.
23. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112, 35-39.
24. Hoshino, Y., Kaneko, M., Kumashiro, H. and Tachibana, R. (1985) Endocrinologic function in schizophrenic patients under haloperidol treatment: Plasma PRL, HGH, and 5-HT levels after L-5-HTP loading. Folia Psychiatr Neurol Japan 39, 25-31.
25. 1 recognition sites. J Recept Res 8, 59-81.
26. Invernizzi, R., Cotecchia, S., Deblasi, A., Mennini, T., Pataccini, R. and Samanin, R. (1981) Effects of MCPP on receptor binding and brain metabolism of monoamines in rats. Neurochem Int 3, 239-244.
27. Iqbal, N., Asnis, G.M., Wetzler, S., Kahn, R.S., Kay, S.R. and van Praag, H.M. (1991) The mCPP challenge test in schizophrenia: Hormonal and behavioral responses. Biol Psychiatry 30, 770-778.
28. Joyce, J.N., Shane, A., Lexow, N., Winokur, A., Casanova, M.F. and Kleinman, J.E. (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8, 315-336.
29. Kahn, R.S., Siever, L.J., Gabriel, S., Amin, F., Stern, R.G., Dumont, K., Apter, S. and Davidson, M. (1992) Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 43, 1-12.
30. Kahn, R.S. and Wetzler, S. (1991) m-Chlorophenylpiperazine as a probe of serotonin receptors: A review. Biol Psychiatry 30, 1139-1166.
31. Kahn, R.S., Wetzler, S., Asnis, G.M. and van Praag, H.M. (1990) Effects of m-chlorophenylpiperazine in normal subjects: A dose-response study. Psychopharmacology 100, 339-344.
32. 1c receptor antagonists. Eur J Pharmacol 164, 445-454.
33. Krystal, J.H., Seibyl, J.P., Price, L.H., Woods, S.W., Heninger, G.R., Aghajanian, G.K. and Charney, D.S. (1993) m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 50, 624-635.
34. Lee, H.S., Bastani, B., Friedman, L., Ramirez, L. and Meltzer, H.Y. (1992) Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. Biol Psychiatry 31, 460-470.
35. Lerer, B., Ran, A., Blacker, M., Silver, H., Weller, M.P., Drummer, D., Elstein, B. and Calev, A. (1988) Neuroendocrine responses in chronic schizophrenia: Evidence for a serotonergic dysfunction. Schizophr Res 1, 405-410.
36. 1A receptor activation in humans. Eur J Clin Pharmacol 37, 17-19.
37. Lowy, M.T. and Meltzer, H.Y. (1988) Stimulation of serum cortisol and prolactin secretion in man by MK-212, a centrally active serotonin agonist. Biol Psychiatry 23, 818-828.
38. Marshall, B.D., Glynn, S.M., Midha, K.K., Hubbard, J.W., Bowen, L.L., Banzett, L., Mintz, J. and Liberman, R.P. (1989) Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 9, 110-115.
39. Meltzer, H.Y. (1992) Dimensions of outcome with clozapine. Br J Psychiatry 160, 46-53.
40. Meltzer, H.Y. and Maes, M. (1995) Effect of pindolol pretreatment on mCPP-induced plasma cortisol and prolactin responses in normal men. Psychiatry Res 58, 89-98.
41. Meltzer, H.Y., Maes, M. and Myung, A.L. (1993) The cimetidine-induced increase in prolactin secretion in schizophrenia: Effect of clozapine. Psychopharmacology 112, 95-104.
42. 2 receptors in chronic schizophrenics. Biol Psychiatry 21, 1407-1414.
43. Mueller, E.A., Murphy, D.L. and Sunderland, T. (1985) Neuroendocrine effects of mCPP, a 5-HT agonist, in humans. J Clin Endocrinol Metab 61, 1179-1184.
44. Murphy, D.L., Mueller, E.A., Hill, J.L., Tolliver, T.J. and Jacobsen, F.M. (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-CPP given intravenously or orally to normal volunteers. Psychopharmacology 98, 275-282.
45. Nasrallah, H.A., Smith, R.E., Dunner, F.J. and McCalley-Whitters, M. (1982) Serotonin precursor effect in tardive dyskinesia. Psychopharmacology 11, 234-235.
46. Owen, R.R., Jr., Gutierrez-Esteinou, R., Hsiao, J., Hadd, K., Benkelfal, C., Lawlor, B.A., Murphy, D.L. and Pickar, D. (1993) Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine (m-CPP) infusions in schizophrenia. Arch Gen Psychiatry 50, 636-644.
47. Preziosi, P., Cerrito, F. and Vacca, M. (1983) Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP. Life Sci 32, 2423-2430.
48. Price, L.H., Charney, D.S., Delgado, P.L., Goodman, W.K., Krystal, J.H., Woods, S.V.V. and Heninger, G.R. (1990) Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 14, 459-472.
49. Ranjan, R., Lee, M.A. and Meltzer, H.Y. (1995) Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia. Biol Psychiatry 37, 678-679.
50. Reynolds, G.P., Rossor, M.N. and Iversen, L.L. (1983) Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia. J Neural Transm (Suppl. 18), 273-277.
51. Rhoades, H.M. and Overall, J.E. (1988) The semistructured BPRS interview and rating guide. Psychopharmacol Bull 10, 101-104.
52. Roth, B.L. and Meltzer, H.Y. (1995) The role of serotonin in schizophrenia. In: Bloom, F.E. and Kupfer, D.J. (Eds.), Psychopharmacology, the Fourth Generation of Progress. Raven Press, New York.
53. 2 receptors: Implications for treating LSD-induced hallucinogens. Psychopharmacology 98, 495-499.
54. Samanin, R., Mennini, T. and Ferraris, A. (1979) m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 308, 159-163.
55. 1B receptor ligands exist? Arch Pharmacol 339, 675-683.
56. Seibyl, J.P., Krystal, J.H. and Price, L.H. (1991) Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to m-CPP in healthy human subjects. Psychiatry Res 38, 227-236.
57. Thompson, P., Maes, M. and Meltzer, H.Y. (1994) Use of placebo controlled models in neuroendocrine challenge studies in psychiatric research. Psychiatry Res 52, 317-326.
58. Whitaker, P.M., Crow, T.J. and Ferrier, I.N. (1981) Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 38, 278-280.
59. Yatham, L.N. and Steiner, M. (1993) Minireview. Neuroendocrine probes of serotonergic function: A critical review. Life Sci 53, 447-463.